Related Experiment Video
Updated: May 15, 2026
07:35
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
Gene transfer for congestive heart failure: update 2013.
1Department of Medicine, University of California San Diego, and VA San Diego Healthcare System, San Diego, Calif., USA.
Translational Research : the Journal of Laboratory and Clinical Medicine
|December 25, 2012
Summary
New gene transfer therapies show promise for treating congestive heart failure (CHF). This review highlights recent advancements in cardiac gene transfer, offering hope for this widespread cardiovascular disease.
Area of Science:
- Cardiology
- Molecular Biology
- Genetics
Background:
- Congestive heart failure (CHF) is a leading cause of illness and death.
- There have been limited therapeutic advancements for CHF in over a decade.
- Preclinical studies have identified key regulators of cardiac function.
Purpose of the Study:
- To review recent progress in cardiac gene transfer for treating congestive heart failure.
- To discuss the potential of gene transfer as a therapeutic strategy for CHF.
Main Methods:
- Review of preclinical studies involving cardiac-directed transgene expression and gene deletion.
- Analysis of clinical gene transfer trials for congestive heart failure.
Main Results:
- Several pivotal regulators of cardiac function have been identified.
- Some identified regulators enhance the function of failing hearts.
- Gene transfer approaches targeting these regulators are entering clinical trials.
Conclusions:
- Cardiac gene transfer represents a promising new therapeutic avenue for congestive heart failure.
- Further clinical development of gene transfer strategies is warranted for CHF treatment.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...